RCM Technologies, Inc. (RCMT) Q2 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presented a mix of positive and negative elements. Revenue growth and strategic expansions are promising, particularly in engineering and healthcare sectors. Despite some revenue declines and delayed cash flows, the company maintains strong gross margins and cash flow recovery. The Q&A section revealed positive analyst sentiment towards strategic partnerships and market positioning. Although immigration challenges and lack of clear dividend plans pose risks, the overall outlook, including optimistic growth projections and strategic market positioning, suggests a positive stock price movement over the next two weeks.

Key Financial Performance

Consolidated Gross Profit $22.3 million for Q2 2025, grew 11.4% over Q2 2024. This is the highest gross profit over the past 13 quarters.

Adjusted EBITDA $8.1 million for Q2 2025, compared to $7.2 million for Q2 2024, a growth of 12.9%.

Adjusted EPS $0.69 for Q2 2025, compared to $0.57 for Q2 2024, a growth of 21.1%.

Health Care Gross Profit $12.3 million for Q2 2025, compared to $10.6 million for Q2 2024, growing 15.4%. Gross margin was 28.7% for Q2 2025, compared to 28.8% for Q2 2024.

School Revenue $37.2 million for Q2 2025, compared to $30.7 million for Q2 2024, growing 21.1%.

Nonschool Revenue $5.6 million for Q2 2025, compared to $6.2 million for Q2 2024, a decrease.

Engineering Gross Profit $6.5 million for Q2 2025, compared to $6.0 million for Q2 2024, growing 8.8%. This was the best Engineering gross profit quarter in the company's history. Gross margin was 24.5% for Q2 2025, compared to 26.5% for Q2 2024.

IT, Life Sciences and Data Solutions Gross Profit $3.5 million for Q2 2025, compared to $3.4 million for Q2 2024, increasing by 3.4%. Gross margin was 39.8% for Q2 2025, compared to 34.9% for Q2 2024.

Operating Cash Flow Weak for Q2 2025 due to delays in over $10 million from 2 major school clients. Over 80% of the delayed amount was collected, with the rest expected in the next quarter.

You have reached the limit Upgrade to access full content

Get started

Operating Highlights

AI-driven equipment qualification: Streamlined compliance protocols and reduced turnaround times in Life Sciences manufacturing sites.

Data integrity solutions: Improved audit readiness and strengthened competitive position with pharma partners.

Life Sciences Engineering Group: Dedicated group established to differentiate RCM in the future.

Inclusion in Russell 2000 Growth Index: First-time inclusion, marking a significant milestone for the company.

Expansion in Health Care Services: New school partnerships and expanded roles with existing clients for the 2025/2026 school year.

Growth in Aerospace and Defense: Exceeded business plan goals by $3 million in revenue for Q2 2025, with new clients and multiyear projects.

Philippines team leverage: Cost-effective scaling and efficient support for new client engagements.

Integrated growth strategy in Engineering: Focus on custom engineering and turnkey EPC solutions for substations and infrastructure builds.

Operational maturity in Engineering: Streamlined project execution and improved cross-unit coordination.

Digital transformation in Life Sciences: Focus on AI and analytics to unlock actionable insights and optimize operations.

Energy Services strategy: Combining custom engineering with turnkey EPC solutions to meet market demand.

Aerospace and Defense focus: Emphasis on supply chain manufacturing, quality engineering, and securing clients requiring high-level clearances.

You have reached the limit Upgrade to access full content

Get started

Risk or Challenges

Economic Uncertainty: The company acknowledges the presence of economic uncertainty, which could impact its operations and strategic objectives.

Capital Markets Exposure: Increased exposure to capital markets due to inclusion in the Russell 2000 Growth Index could lead to heightened scrutiny and volatility.

Seasonality in Operations: Significant seasonality in Q3 due to summer school closings and workforce vacations makes forecasting challenging and could impact financial performance.

Delayed Payments: Over $10 million in delayed payments from two major school clients in Q2, though partially collected, highlights potential cash flow risks.

Engineering Gross Margin Volatility: Engineering gross margins are volatile, with fluctuations between 22% and 26%, which could affect profitability.

Regulatory and Compliance Risks: The company operates in regulated environments, particularly in Life Sciences, which requires adherence to compliance protocols and could pose risks if not managed effectively.

Supply Chain and Talent Acquisition: Challenges in supply chain manufacturing and quality engineering, as well as the need for specialized talent, particularly in Aerospace and Defense, could impact operational efficiency.

Dependence on Key Clients: Dependence on major school clients and specific industries like Aerospace and Defense could pose risks if client relationships or industry conditions change.

You have reached the limit Upgrade to access full content

Get started

Guidance & Outlook

Health Care Services Group: Entering the 2025/2026 school year with strong momentum, expanding roster of new school partners, and commitments from existing clients to broaden RCM's role in staffing schools. Robust pipeline of opportunities positions the group for continued growth.

Life Sciences, Data and Solutions: Momentum driven by strategic focus on innovation and operational excellence. Investments in AI-driven equipment qualification and advancements in data integrity solutions are expected to streamline compliance, reduce turnaround times, and improve competitive positioning. Building a dedicated Life Sciences Engineering Group to differentiate RCM for the future.

Engineering - Energy Services: Sharp acceleration in activity expected in the second half of the year. Focus on custom engineering and turnkey EPC solutions to meet surging market demand. Growth anticipated in grid modernization, infrastructure upgrades, and data center expansion. Operational maturity and advanced technologies to streamline project execution and enhance market positioning.

Aerospace and Defense Group: Anticipates record year in 2025. Continued growth expected due to ramp-up on existing programs, addition of new clients, and success in supply chain manufacturing and quality engineering. Opportunities in hand are expected to drive growth throughout 2025, with a focus on clients requiring expertise in software, systems, and high-level security clearances.

Consolidated Financial Outlook: Anticipates low double-digit growth in adjusted EBITDA for the second half of fiscal 2025. Expects Q4 2025 to produce the highest adjusted EBITDA quarter for the year despite seasonality challenges in Q3.

You have reached the limit Upgrade to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit Upgrade to access full content

Get started

Key Q&A

Q:Could you give us some color on how your multiyear preferred partner agreements are helping you accelerate into the data center infrastructure and grid modernization sector?

A:The multiyear preferred partner agreements are benefiting from initiatives that have been in place for years, leading to marquee projects that enhance brand equity and attract industry attention. RCM has improved its coordination and integration of operations over the last 12-18 months, which has been rolled out to the marketplace. The industry is experiencing a historic surge in spending, and RCM is well-positioned to benefit from this protracted secular bull market.

Q:Are most of your new contracts in the health care space still K-12, or are you expanding into other areas of education?

A:Most new contracts are still primarily in K-12. The company has added a dozen new contracts, half of which are expected to significantly impact revenue for the 2025/2026 school year. While other areas are being considered, the focus remains on K-12.

Q:Is the trend of taking new business at the expense of competitors expected to continue as you add districts?

A:Yes, the company expects this trend to continue. While they are gaining market share from competitors, the high-growth market allows for growth without necessarily taking market share. As a leader in the fragmented K-12 market, the company sees significant opportunities to demonstrate expertise and win against local and regional competitors.

Q:Did you give the breakout of school and other health care revenues?

A:Yes, the breakout was $37.2 million for schools and $5.6 million for non-schools for the quarter.

Q:Can you provide details on your internal training program in health care?

A:The internal training program identifies potential candidates for schools and trains them in several training centers. The program focuses mainly on paras but also includes RBTs and other roles. Specific details were not disclosed for competitive reasons.

Q:What is the status of the international nurse program?

A:Visa retrogressions have delayed the arrival of nurses, but 15-20 nurses are expected this year or early next year. If visa retrogressions are resolved, the company has a pipeline of 500 nurses interested in coming to the U.S. Immigration challenges remain a gating factor for growth.

Q:Is the current level of Engineering GM indicative of where the business is now?

A:Yes, but the business is volatile, and margins can fluctuate based on the mix of projects. The company focuses on gross profit dollars and cash flow management rather than specific margin percentages.

Q:Can new contracts with new clients in Engineering start at lower gross margins and expand over time?

A:Not necessarily. While the company may bid lower margins for strategic clients, the focus is on fair and competitive margins. Lower margins are more likely due to fixed-price contracts with subcontractor costs or competitive segments like Aerospace.

Q:Should we expect receivables to go up at the end of Q2 due to the school year ending?

A:Yes, receivables may increase due to schools running out of money on their POs, but the company always gets paid by schools. Receivables are expected to normalize in Q3.

Q:Is immigration and supply a gating factor for growth in the health care segment?

A:Yes, immigration challenges limit the number of nurses coming to the U.S. While the company can grow without immigration improvements, resolving these issues could significantly enhance growth.

Q:Would implementing a dividend make sense given the company's current position?

A:Management acknowledges that a dividend could make sense given the company's strong position, reduced share count, and clean balance sheet. However, they are also focused on maintaining flexibility for growth opportunities and strategic partnerships.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details about the internal training program in health care, citing competitive reasons. Additionally, they did not commit to a timeline or specifics regarding the implementation of a dividend, leaving the decision open-ended.

You have reached the limit Upgrade to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

RCMT Transcript

RCM Technologies, Inc. (RCMT) Q3 2025 Earnings Call Transcript

Unknown11-6

The earnings call reveals mixed performance: strong growth in school revenue and engineering gross profit, but declines in non-school revenue and life sciences gross profit. Margins are mixed, with some improvement but also declines. The Q&A highlights uncertainties, like visa issues for foreign candidates and persistent high medical costs. Despite optimistic long-term guidance, immediate concerns and lack of clear execution details temper positive sentiment. Without a market cap, a neutral prediction accounts for these balanced positives and negatives.

RCM Technologies, Inc. (RCMT) Q2 2025 Earnings Call Transcript

Positive8-7

Earnings call transcript: RCM Technologies Q1 2025 beats EPS forecast, stock surges

Positive5-8

The earnings call reveals strong financial performance with increased gross profit, EBITDA, and EPS. Positive growth in K-12 services and aerospace sectors, alongside reduced net debt and improved cash flow, indicate robust operational health. Despite some margin variability, guidance remains optimistic. The share repurchase plan further supports stock price appreciation. The Q&A section didn't reveal significant risks, supporting a positive outlook. However, lack of specific guidance and margin concerns temper expectations, placing the prediction in the 'Positive' range (2% to 8%).

RCM Technologies, Inc. (RCMT) Q4 2024 Earnings Call Transcript

Unknown3-13

The earnings call highlights several challenges: flat gross profit, declining EBITDA and EPS, high medical costs, canceled orders, increased legal expenses, and volatile margins. The absence of a share repurchase program and macroeconomic uncertainties add to the concerns. Although healthcare and school revenue show growth, the overall sentiment is negative due to financial difficulties and risks. The Q&A reveals high tax rates and management's avoidance of specific impact details, further dampening sentiment. The negative aspects outweigh the positives, leading to a likely negative stock price reaction.

RCMT Report

RCM TECHNOLOGIES, INC. 10-Q

10-Q

2024-11-07

RCM TECHNOLOGIES, INC. 10-Q

10-Q

2024-08-08

RCM TECHNOLOGIES, INC. 10-Q

10-Q

2024-05-09

RCM TECHNOLOGIES, INC. 10-K

10-K

2024-03-14

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.